PDF(Pubmed)
Abstract：
UNASSIGNED: Recent theories on the possible interactions between the intestinal parasites and COVID-19 have stated that these co-infections may cause immune imbalance and further complications in the affected patients. Until now, there is no data about Blastocystis subtypes as an intestinal parasite in COVID-19 patients. Therefore, the present work was done to evaluate the molecular prevalence of Blastocystis spp. and related risk factors in Iranian patients with COVID-19.
UNASSIGNED: Stool samples were gathered from 200 COVID-19 patients and 200 control, being matched regarding age, gender and residence. Then, stool samples were surveyed by parasitological methods, including direct slide smear and formalin-ether concentration. In the following, PCR and sequencing were used to detect Blastocystis spp. and their subtypes.
UNASSIGNED: The frequency of Blastocystis spp. in patients with COVID-19 (7.5%; 15/200 by molecular method vs. 6%; 12/200 by microscopy method) was slightly higher than in individuals without COVID-19 (4.5%; 9/200 by molecular method vs. 4%; 8/200 by microscopy method), this difference was not statistically significant (P value = 0.57 for molecular method vs. P value = 0.81 for microscopy method). Regarding associated factors for Blastocystis spp., we found significant differences regarding the residence (rural), loose and watery stool with diarrhea, and duration of treatment (6 weeks <) in the COVID-19 group. Blastocystis ST3 was the most common subtype in the patients with COVID-19 and control group.
UNASSIGNED: Based on this results, health education, improved sanitation and good personal hygiene are highly recommended to prevent Blastocystis in COVID-19 patients.
UNASSIGNED: Stool samples were gathered from 200 COVID-19 patients and 200 control, being matched regarding age, gender and residence. Then, stool samples were surveyed by parasitological methods, including direct slide smear and formalin-ether concentration. In the following, PCR and sequencing were used to detect Blastocystis spp. and their subtypes.
UNASSIGNED: The frequency of Blastocystis spp. in patients with COVID-19 (7.5%; 15/200 by molecular method vs. 6%; 12/200 by microscopy method) was slightly higher than in individuals without COVID-19 (4.5%; 9/200 by molecular method vs. 4%; 8/200 by microscopy method), this difference was not statistically significant (P value = 0.57 for molecular method vs. P value = 0.81 for microscopy method). Regarding associated factors for Blastocystis spp., we found significant differences regarding the residence (rural), loose and watery stool with diarrhea, and duration of treatment (6 weeks <) in the COVID-19 group. Blastocystis ST3 was the most common subtype in the patients with COVID-19 and control group.
UNASSIGNED: Based on this results, health education, improved sanitation and good personal hygiene are highly recommended to prevent Blastocystis in COVID-19 patients.
摘要：
未经证实：关于肠道寄生虫与COVID-19之间可能相互作用的最新理论指出，这些共同感染可能会导致受影响患者的免疫失衡和进一步的并发症。直到现在,没有关于COVID-19患者中作为肠道寄生虫的囊胚原虫亚型的数据。因此,本研究的目的是评估囊胚的分子患病率.伊朗COVID-19患者的相关危险因素。
未经证实：生物学：收集了200名COVID-19患者和200名对照的粪便样本，在年龄上匹配，性别和居住地。然后，通过寄生虫学方法调查粪便样本，包括直接载玻片涂片和福尔马林-乙醚浓缩。在下文中，PCR和测序用于检测囊胚。和它们的亚型。
未经证实：囊胚的频率。在COVID-19患者中（7.5%；15/200，通过分子方法与6％；显微镜方法为12/200）略高于无COVID-19的个体（4.5％；分子方法为9/2004%；8/200显微镜法)，这种差异没有统计学意义(分子方法与显微镜法P值=0.81)。关于囊胚的相关因素。,我们发现在居住地(农村)方面存在显著差异，腹泻的松散和水样的大便，COVID-19组的治疗时间（<6周）。囊胚ST3是COVID-19患者和对照组中最常见的亚型。
未经评估：基于此结果，健康教育,强烈建议改善卫生条件和良好的个人卫生，以预防COVID-19患者的囊胚病。
未经证实：生物学：收集了200名COVID-19患者和200名对照的粪便样本，在年龄上匹配，性别和居住地。然后，通过寄生虫学方法调查粪便样本，包括直接载玻片涂片和福尔马林-乙醚浓缩。在下文中，PCR和测序用于检测囊胚。和它们的亚型。
未经证实：囊胚的频率。在COVID-19患者中（7.5%；15/200，通过分子方法与6％；显微镜方法为12/200）略高于无COVID-19的个体（4.5％；分子方法为9/2004%；8/200显微镜法)，这种差异没有统计学意义(分子方法与显微镜法P值=0.81)。关于囊胚的相关因素。,我们发现在居住地(农村)方面存在显著差异，腹泻的松散和水样的大便，COVID-19组的治疗时间（<6周）。囊胚ST3是COVID-19患者和对照组中最常见的亚型。
未经评估：基于此结果，健康教育,强烈建议改善卫生条件和良好的个人卫生，以预防COVID-19患者的囊胚病。
